ACE and hydrops fetalis: Other barriers such as perceived patient nonadherence, adverse effects of MRAs, and concerns about polypharmacy and competing comorbidities have been described as barriers to implementation of various guidelines, including ACE inhibitor and beta‐blocker use in HF.20 Despite these known patient‐related factors that may limit guideline adherence, this study supports past research that suggests current performance measurement systems do not effectively capture these barriers and tend to focus on standard medical contraindications rather than other contextual factors.22